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1. Introduction 
Advanced endoscopy can be used to insert stents (hollow tubes) into various sites of the 
gastrointestinal tract and this has proved to be a major therapeutic advance. Stents can hold 
open strictured areas in the oesophagus, the biliary tree, the colon and the gastroduodenal 
region. Stents are usually positioned in order to overcome stricturing associated with 
cancerous tumours. They are used as definitive treatment, as a bridge to surgery, and for 
palliation of obstructive symptoms. In the setting of incurable gastrointestinal cancer, the 
endoscopic placement of such stents allows palliation of symptoms non-invasively, and is 
an attractive alternative to surgery. Stents can also be used in benign disease of the 
gastrointestinal tract. 
The basic principles of stent insertion involve the initial placement of a guidewire, (and 
sometimes an overrunning introducing catheter) across the region to be stented, using 
endoscopic vision and often fluoroscopic guidance too. The stent is advanced over the 
guidewire until it traverses the area to be stented. In the case of self-expanding stents, the 
restraining mechanism is then released to deploy the stent. 
Gastrointestinal stent insertion is not the sole domain of the endoscopist. Gastrointestinal 
stents are also placed non-endoscopically by radiologists. For example, interventional 
radiologists use fluoroscopic guidance to position oesophageal stents in the oesophagus, or 
can use a combination of sonography and percutaneous transhepatic cholangiography to 
place biliary stents in the biliary tree. The route of stent insertion may be influenced by local 
expertise, but the indications for stent insertion are usually those benefitting from a 
multidisciplinary approach involving endoscopists, surgeons, interventional radiologists 
and oncologists. Gastrointestinal stent insertion is an area of medicine where the territorial 
boundaries of interventional endoscopists, minimally invasive surgeons and interventional 
radiologists are increasingly blurred. 
2. Technology of stents 
2.1 Simple plastic stents 
Initially endoscopic stents were solely plastic. Up until the 1990s, rigid plastic stents were 
used to stent stricturing oesophageal cancers. However the development of safer Self-
Expanding Metal Stents (SEMS) has rendered these rigid plastic oesophageal stents obsolete. 
Today plastic stents are mainly confined to use in the biliary tree and pancreas. These plastic 
stents are usually composed of one of three polymers - polyethylene, polyurethane or 
Teflon. Plastic stents used in the biliary tree and pancreas may be straight with anchoring 
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side-flaps to prevent migration. Alternatively, pigtailed stents may be used in the biliary 
tree. The curled end of a pigtail stent is straightened over the guidewire during positioning 
and the pigtail resumes its shape once the guidewire has been removed. The pigtail anchors 
the stent in position. The diameter of a plastic stent is usually described in terms of the 
French scale, where 1 French (Fr) is 0.33 mm. Thus a 6 Fr stent has a diameter of 2 mm. The 
maximum diameter of a simple plastic stent is limited by the maximum size of an 
endoscope’s operating channel size at 12 Fr or 4 mm.  
 
 
Fig. 1. Straight plastic stents used for biliary and pancreatic stenting  
 
 
Fig. 2. Pigtail stent used for biliary stenting 
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2.2 Self-expanding stents 
Although simple plastic stents still have a role in biliary and pancreatic stenting, 
technological improvements have led to the development of smarter stents. Self-Expanding 
Metal Stents (SEMS) are positioned while collapsed, using a small calibre introducer. 
Insertion of SEMS is easier, safer, with a reduced risk of perforation, and much reduced 
need for prior stricture dilatation. 
Metals in SEMS need to be biocompatible i.e. biologically innocuous when functioning in 
patients. Shape memory alloys are ‘intelligent’, possessing the ability to recover a previously 
defined length or shape when deployed in the patient (Tarnita et al., 2009). There are several 
types and sizes of SEMS on the market. Each has its own characteristics in terms of radial 
forces exerted, foreshortening on deployment, and flexibility. SEMS can be made from 
stainless steel e.g. Z-stent® (Cook Medical, Bloomington, IN, USA) or from alloys. Nitinol is 
an alloy of nickel and titanium used in Ultraflex® stent (Boston Scientific, Natick, MA, USA) 
and Alimaxx E® stent (Alveolus, Charlotte, NC, USA). Elgiloy, a cobalt /chromium /nickel 
alloy, is used in Wallstent® (Boston Scientific). 
 
 
Fig. 3. Different sizes of Self-Expanding Metal Stents used in oesophageal stenting 
SEMs should be fluoroscopically opaque to aid positioning, and should be easily deployable 
via a small calibre introducer. They are introduced in a collapsed position, being run over a 
guidewire positioned through the region to be stented. Once in position the constraining 
mechanism is released and the stent expands, exerting radial forces on any stricturing lesion 
thus increasing the lumen of the area being stented. SEMS are designed to expand to a 
diameter of more than 20mm. The bare metal strands of an uncovered stent may embed in 
the underlying tumour and serve to anchor the stent in position. Through pressure necrosis, 
the struts of the stent migrate into the mucosa and submucosa of the gut wall. A fibrous 
reaction with chronic lymphocytic infiltration occurs, as the stent becomes embedded in 
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collagen and fibrous tissue. A chronic lymphocytic reaction occurs in the normal tissue 
underlying the proximal and distal ends of the stent (Bethge et al.,1996). Once in situ the 
stent should be MRI compatible. 
 
 
Fig. 4. Uncovered Self-Expanding Metal Stent used in biliary stenting 
SEMS may be covered with a silicone membrane to reduce the risk of tumour in-growth and 
to seal fistulas. However fully covered stents are less likely to embed in the underlying 
tissues, and have an increased risk of stent migration compared to uncovered stents. 
Therefore, partially covered stents have been developed with flared uncovered segments at 
both ends to anchor on to the tissue. Fully covered SEMS are also increasingly used in 
benign oesophageal disease, such as non-malignant strictures and anastomotic leaks. The 
Polyflex ® stent (Boston Scientific, Natick, MA, USA) is a removable self-expanding plastic 
stent for use in the management of benign and malignant oesophageal strictures. Such a 
removable self-expanding plastic stent allows temporary stent insertion for benign 
oesophageal disease and for patients undergoing neoadjuvant chemotherapy prior to 
oesophagectomy. Recently biodegradable stents have been developed which slowly break 
down over time, e.g. the SX-Ella Esophageal Degradable BD stent®, (ELLA-CS, Hradec-
Kralove, Czech Republic) made from the biodegradable polymer poly-dioxanon, and the 
Tanaka-Marui stent (Marui Textile Machinery Co., Osaka, Japan) composed of biodegradable 
poly-L-lactic acid monofilaments. 
Potential complications of SEMS insertion include perforation, tumour overgrowth or 
ingrowth, and stent migration. Newer stents are being developed with the aim of increasing 
technical and clinical success rates, while reducing complication rates. Other areas of 
development include radioactive or drug-eluting stents for malignant disease.  
3. Oesophageal stents for malignant oesophageal obstruction 
Patients with oesophageal cancer experience progressive dysphagia and weight loss. 
Radical surgery in the form of oesophagectomy offers the only chance of cure. 
Unfortunately, patients often present late with inoperable tumours, or are too frail to be 
considered for surgery which itself caries significant morbidity and mortality. Dysphagia 
is a distressing and unpleasant symptom. Relief of dysphagia, so that patients can 
swallow again, is very important in the treatment of oesophageal cancer. Oesophageal 
stents are an excellent option for the palliation of dysphagia. In contrast to other treatment 
modalities like endoscopic laser or brachytherapy, stents are widely available and are not 
restricted to specialised centres. They can be inserted under endoscopic or fluoroscopic 
guidance or a combination of both. They rapidly relieve dysphagia, and can be used in 
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patients with advanced inoperable disease or in patients too frail to have chemotherapy or 
radiotherapy. 
The first stents used in malignant dysphagia were rigid plastic stents. Placing such rigid 
stents, and the necessary prior stricture dilatation carried a substantial risk of perforation. 
SEMS were developed in the early 1990s. Their design allows them to be preloaded onto a 
delivery mechanism typically measuring 5-10mm in diameter. Consequently little or no 
dilatation is needed prior to stent insertion. Oesophageal SEMS are deployed over a 
guidewire after delineating the margins of the stricture endoscopically. Although the stents 
are usually deployed under fluoroscopic guidance, increasingly many endoscopists deploy 
them under direct endoscopic vision with the endoscope positioned alongside the 
guidewire–stent assembly. The diameter of most fully deployed oesophageal SEMS varies 
between 16 and 24 mm and their length varies between 7 and 15 cm. SEMS are usually 
partially or fully covered with a membrane to prevent tumour ingrowth through the metal 
mesh. 
Early studies comparing traditional rigid plastic stents and SEMS demonstrated the 
superiority of the latter in several domains. Knyrim et al (1993) compared the two types of 
stents and showed SEMS and rigid plastic stents to be equivalent in their improvement of 
dysphagia, 30 day mortality and re-intervention rates. However, metal stents were 
associated with fewer complications, shorter hospitalisation after stent placement and 
superior cost effectiveness (Knyrim et al., 1993). Subsequent randomised studies and a 
retrospective review produced similar results (De Palma et al., 1996; Roseveare et al., 1998; 
Eickhoff et al., 2005). Furthermore, the perforation rates and early mortality rates were lower 
in those patients receiving SEMS. Rigid plastic stents are no longer used in oesophageal 
cancer. 
Although the procedure-related complication rates are lower with SEMS, these devices are 
still subject to late complications including stent migration and stent occlusion due to food 
bolus or tumour overgrowth. One study has suggested that such late complications are 
more common with SEMS compared to rigid plastic stents (Kozarek et al., 1996). In a 
retrospective study of SEMS for malignant dysphagia, repeat endoscopy to address 
complications was needed in 46 of 97 patients, and in 10 of these a further stent had to be 
inserted (Ross et al., 2007). Acid reflux frequently occurs when stents are placed across, and 
thus hold open, the gastro-oesophageal junction. Patients with stents traversing the gastro-
oesophageal junction should experience fewer reflux symptoms if they take acid 
suppressive drugs to decrease gastric acid production, prokinetic drugs to hasten stomach 
emptying, avoid eating within 2-3 hours of bed-time, and elevate the head of the bed. 
Despite these measures patients can still experience significant reflux symptoms and 
consequently stents with inherent anti-reflux mechanisms have been developed e.g. the 
Oesophageal Z stent with Dua anti-reflux valve ®, (Cook Medical, Bloomington, USA), and the 
FerX-ELLA Esophageal Stent – Boubella ®, (ELLA-CS, Hradec-Kralove, Czech Republic). 
3.1 Types of expandable oesophageal stents used for oesophageal cancer 
The majority of commercially available oesophageal SEMS are made of nitinol or stainless 
steel. Covered stents are less prone to tumour ingrowth, but more prone to migration. 
Consequently partially covered stents have been developed. These have a central covered 
portion which is placed across the oesophageal tumour with the two ends left uncovered to 
allow embedding and anchoring into the adjacent tissue. Patients with partially covered stents 
have less tumour ingrowth and fewer interventions for recurrent dysphagia than patients with 
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bare metal stents (Vakil et al; 2001; Saranovic et al., 2005). Studies comparing different 
commercially available covered stents have shown all the studied stents to have similar 
efficacy and complication rates (May et al., 1996; Sabharawal et al., 2003; Siersema et al., 2001). 
 
 
Fig. 5. Endoscopic view immediately after deployment of a SEMS for oesophageal cancer 
In addition to SEMS, an self-expanding plastic stent made of polyester and covered with 
silicone (Polyflex®, Boston Scientific, Natick, MA, USA) has become available. Randomised 
controlled studies have shown that it can be successfully placed in the majority of cases and 
produces similar improvements in dysphagia when compared to SEMS (Conio et al., 2007; 
Verschuur et al., 2008). However, self-expanding plastic stents are associated with more 
complications, in particular stent migration (Conio et al., 2007), and for this reason are not 
routinely used for the treatment of malignant oesophageal obstruction. 
3.2 Effect of oesophageal stenting on symptom palliation and quality of life 
SEMS improve swallowing in malignant dysphagia. When formally studied, SEMS have 
consistently been shown to improve dysphagia scores (Knyrim et al., 1993). Oesophageal 
SEMS enable patients to ingest semi-solids but rarely improve dysphagia to the point of 
taking a completely normal diet. Patients with SEMS run the risk of causing food bolus 
obstruction if they attempt to take an unrestricted diet. Roast meats and crusty bread are 
particular culprits in blocking stents. In addition to the symptomatic improvement some 
studies have documented a benefit in the overall quality of life (Diamantis et al., 2011). 
Karnofsky scores were shown to significantly improve from a median of 40 before SEMS 
insertion to a median of 65 after SEMS insertion (Knyrim et al., 1993). Other advantages of 
SEMS include nutritional benefits, with patients receiving SEMS enjoying food more and 
maintaining their weight longer compared to patient receiving rigid plastic stents 
(Roseveare et al., 1998). 
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3.3 Comparison of stenting with other palliative treatments in malignant dysphagia 
Alternative treatments for malignant dysphagia include endoscopic laser and brachytherapy. 
A multi-centre randomised trial found that SEMS improved dysphagia quicker than single 
dose brachytherapy, but brachytherapy was associated with better long term improvements in 
dysphagia, fewer complications and better quality of life scores (Homs et al., 2004). A Belgian 
centre retrospectively compared 125 patients with malignant dysphagia treated with 
endoscopic laser, rigid plastic stents and SEMS. Dysphagia improved significantly in all 3 
groups but the rate of complications was significantly higher in both stent groups, compared 
to endoscopic laser (Gevers et al., 1998). In a prospective comparison, SEMS insertion was as 
safe and effective as laser combined with radiotherapy for inoperable oesophageal cancer 
(Königsrainer et al., 2000). SEMS insertion seems to be the preferred option for treating 
malignant dysphagia, since SEMS are widely available, relatively easy to place endoscopically 
or under fluoroscopic guidance, and provide rapid symptom relief. Brachytherapy, although 
efficacious remains a treatment that is not widely available. 
3.4 Stents for benign oesophageal peptic strictures  
Benign oesophageal strictures are most commonly caused by chronic reflux of gastric acid 
into the distal oesophagus. Such benign peptic strictures can lead to significant dysphagia. 
They are normally readily treated by endoscopic dilatation and acid suppression therapy. 
Rarely, the stricture repeatedly recurs within a few weeks. In these patients alternative 
treatments to repeated dilatation and acid suppressants may be needed. Although surgery is 
the mainstay of treatment in these refractory cases, oesophageal stenting should be 
considered in those less suitable for surgery. The ideal oesophageal stent for use in benign 
disease should, as with malignant disease, be easy to place, use a small calibre delivery 
mechanism and have a low rate of migration. However it should also be easy to retrieve, 
easy to reposition, and have low rates of insertion and removal related complications 
(Sharma & Kozarek, 2010). 
Data on the use of SEMS in benign oesophageal strictures come from case reports and case 
series. These reports show that SEMS are associated with high rates of complications. The 
most commonly reported are stent migration occurring in 12.5-31%, new stricture formation 
in 20-100% and fistula formation in 6-33% of patients (Sandha & Marcon, 1999; Fiorini et al., 
2000; Ackroyd et al., 2001; Wadhwa et al., 2003). Stent migration is more likely to occur with 
covered stents while uncovered stents or partially covered stents become embedded in the 
tissue making their removal difficult and traumatic. These complications rates are generally 
felt to be too high to justify in the treatment of benign disease. Therefore SEMS are best 
avoided in benign oesophageal strictures (Sharma & Kozarek, 2010). 
In distinction to metal stents, expandable plastic stents such as the removable Polyflex® stent 
have been increasingly studied in benign oesophageal strictures that do not respond to 
conventional treatments. A recent meta-analysis of fully covered self-expanding metal and 
plastic stents has shown that the improvement in dysphagia was significantly better in 
patients receiving a Polyflex® stent (55.3%) compared to those receiving a nitinol stent 
(21.8%) (Thomas et al., 2011). 
A more exciting prospect in the treatment of benign oesophageal conditions has been the 
recent development of biodegradable stents. Such stents are designed to stay in place for a 
few weeks before disintegrating. This avoids the need for further procedures to remove the 
stent. Some small series have now reported on their efficacy in benign strictures (Saito et al., 
2007; Repici et al., 2010).  
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3.5 Stents for malignant tracheo-oesophageal fistulas 
Malignant tracheo-oesophageal fistulas may arise from infiltration of oesophageal cancers into 
the respiratory tract, or cancers of the trachea and bronchi infiltrating into the oesophagus. 
These life-threatening connections between the digestive tract and the airways are usually 
difficult to treat and are associated with poor prognosis. Patients receiving best supportive 
treatment survive a median of 22 days (Burt et al., 1991).There are no randomised controlled 
data on the use of SEMS in these patients. However, several case series have demonstrated 
that covered SEMS can lead to fistula occlusion in 70-100% of patients (May & Ell, 1998). A 
retrospective study has shown covered SEMS to be more successful at fistula occlusion 
compared to rigid plastic stents, 92% vs. 77% (Low & Kozarek, 1998). Furthermore, successful 
occlusion of the fistula was associated with improved 30 day survival, 90% vs. 25% 
(Dumonceau et al., 1999) and overall survival, 15.1 vs. 6.2 weeks (Shin et al., 2004).  
3.6 Stents for oesophageal perforations and leaks 
Spontaneous and iatrogenic perforations of the oesophagus also carry a very high mortality 
and morbidity. Early diagnosis and prompt treatment are essential to achieve a good 
outcome. 
Spontaneous oesophageal perforation as a result of vomiting (Boerhaave’s syndrome) is a 
surgical emergency, requiring surgical intervention within hours of the perforation. Rarely, 
patients present late and there have been a handful of reports of oesophageal SEMS being 
used in the treatment of spontaneous oesophageal perforations if the patient has presented 
late (Eubanks et al., 1999; Chung et al., 2001).  
Iatrogenic perforations of the oesophagus are more common than spontaneous perforations. 
They usually occur at endoscopy, most frequently when malignant stricture dilatation is 
undertaken. The diagnosis of perforation is usually obvious and rapid. Although iatrogenic 
oesophageal perforation is life-threatening, contamination of the mediastinum and pleural 
space with stomach contents is less problematic compared to spontaneous perforation, since 
the patient is fasted. Small case series have shown that insertion of a covered SEMS, together 
with thoracostomy tube drainage of the pleural space and antibiotic administration is a 
successful strategy in sealing off iatrogenic perforations (Siersema et al., 2003). Prompt stent 
insertion (average delay 45 minutes) after iatrogenic oesophageal perforation leads to 
minimal morbidity compared to delayed treatment, and produces results similar to surgical 
treatment (Fischer et al., 2006). It has to be emphasised that the clinical state of patients may 
individualise therapy for oesophageal perforations; although most centres consider surgery 
as first-line therapy (Keeling et al., 2010; Kiernan et al., 2010), endoscopic stenting is an 
option in many patients (Johnsson et al., 2005; van Heel et al., 2010). 
3.7 Oesophageal stenting for anastomotic leaks 
Post-operative anastomotic leaks are another area where oesophageal stents are increasingly 
used. Case series of anastomotic leaks following upper gastrointestinal surgery have 
demonstrated high success and low complications rates, with patients returning to eating 2 
days after stent insertion. 
3.8 Stenting for bleeding oesophageal varices 
Oesophageal stents have recently been used to arrest bleeding from oesophageal varices in 
patients with portal hypertension. Bleeding from oesophageal varices has a high mortality, 
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especially in patients with advanced liver disease. Bleeding is usually controlled by 
endoscopic band ligation of the varices, and vasopressor medication to decrease portal 
pressure. If these measures fail, the bleeding can be controlled with the insertion of a 
Sengstaken-Blakemore tube which tamponades the varices. Balloon tamponade is a 
temporary measure often used as a bridge to treatment with a transjugular intrahepatic 
portosystemic stent shunt (TIPSS). 
A covered self-expanding oesophageal stent (SX-Ella Stent Danis®,ELLA-CS, Hradec-Kralove, 
Czech Republic) has recently been developed as another treatment option in variceal bleeding. 
It is an alternative to balloon tamponade in patients who are not suitable for TIPSS or in whom 
Sengstaken-Blakemore tube insertion is not possible, has failed or is complicated by 
oesophageal perforation. The SX-Ella Stent Danis® delivery mechanism is inserted over a 
guidewire that has been endoscopically placed in the stomach. The endoscope is then 
withdrawn and the delivery mechanism advanced through the oesophagus into the stomach. 
A balloon located at the stent’s distal end is then inflated, and the whole mechanism is 
withdrawn until the balloon reaches the cardia and resistance is felt. The stent, now positioned 
in the distal oesophagus can be deployed, followed by balloon deflation and removal of the 
delivery mechanism. The stent can also be placed without prior endoscopy in emergency 
situations. Once deployed, the tamponading stent permits ongoing oral nutrition, unlike 
balloon tamponade. Case series show that such stents are efficacious in bleeding oesophageal 
varices. They can be successfully placed in the majority of patients and are removed within 14 
days of insertion. The only complication that has been reported is of oesophageal ulceration 
(Hubmann et al., 2006; Zehetner et al., 2008; Wright et al., 2010). 
4. Gastroduodenal stents 
Recurrent and distressing vomiting due to gastric outlet obstruction occurs in some patients 
with pancreatic cancer, distal gastric cancer, duodenal cancer and some metastatic cancers. 
Most of these patients have advanced and inoperable disease, and only a few months of life 
remaining. Until recently the only treatment to prevent relentless vomiting and allow oral 
nutrition was the fashioning of a surgical gastroenterostomy to bypass the antro-pyloro-
duodenal region. Even though such surgery can now often be done laparoscopically, 
complications are not uncommon in such patients who are often malnourished and 
frequently have comorbidities. The development of gastroduodenal stent insertion offers a 
noninvasive means of palliating vomiting without surgery (Martin & Laasch, 2004; Lowe et 
al., 2007; Kim et al., 2007).  
Gastroduodenal stents are of the SEMS variety and are positioned under direct endoscopic 
vision, and with fluoroscopic guidance. Before stent placement is attempted, a period of 
gastric drainage using a wide-bore nasogastric tube is recommended. Drainage of gastric 
contents will improve endoscopic views and reduce the risk of vomiting and aspiration 
during the procedure. At endoscopy, the stricture’s proximal anatomy is assessed but 
usually the endoscope’s diameter is too large to allow safe negotiation through the stricture. 
The stricture can be outlined by fluoroscopy after the injection of a contrast agent. A 
guidewire is then passed down the operating channel of a therapeutic endoscope and 
advanced through the stricture. The stent assembly is then passed over the wire and 
positioned so that its ends overlap the ends of the stricture. Once fluoroscopy confirms a 
satisfactory position, the SEMS is deployed. An alternative method of gastroduodenal stent 
insertion involves a radiologist placing the stent via the oral route using fluoroscopy alone.  
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Once a gastroduodenal stent has been sited, patients can resume oral intake without 
vomiting. Patients should be advised to chew all foods well, and initially a soft diet is 
recommended. Patients who remain on a semi-solid diet are less likely to experience food 
impaction in their stent, but many patients are able to tolerate all food consistencies. 
Following gastroduodenal stent insertion, potential early complications include bleeding 
and perforation. Late complications include distal stent migration, and stent obstruction by 
tumour ingrowth, reactive tissue hyperplasia, tumor overgrowth, and food impaction.  
4.1 Endoscopic stenting v. gastrojejunostomy in malignant gastric outlet obstruction 
Most comparisons of gastroduodenal stent insertion with surgical gastrojejunostomy in 
malignant outlet obstruction have been retrospective. There is little in the way of large 
randomised trial data prospectively comparing these two palliative procedures. Despite the 
limitations of studies to date, some conclusions can be drawn (Gaidos & Draganov, 2009; Ly 
et al., 2010). Compared to surgical gastrojejunostomy, gastroduodenal stent insertion is 
associated with a shorter hospital stay, fewer costs (Johnsson et al., 2004) and fewer 
complications at the time of intervention. Stent insertion also leads to faster resumption of 
oral food intake than surgical gastrojejunostomy (Maettani et al., 2004; Ly et al., 2010). 
However, in the longer term there may be stent migration or obstruction, and long term 
results are better with surgery (Jeurnink et al., 2010).  
4.2 Combined biliary and gastric outlet obstruction 
By the time an inoperable pancreatic cancer causes gastric outlet obstruction, there has often 
already been biliary obstruction. Endoscopic access to the duodenal papilla is important for 
biliary stenting and jaundice relief (see below). A gastroduodenal stent will cover the 
duodenal papilla, but with an uncovered stent some endoscopic access to the papilla can be 
achieved through the holes in the metal mesh. However it is technically very difficult to 
perform biliary stenting though the mesh of an uncovered metal duodenal stent, and biliary 
stent insertion or exchange is more readily achieved percutaneously via the transhepatic 
cholangiographic route once a gastroduodenal stent is present. Covered gastroduodenal 
stents will further confound endoscopic access to the duodenal papilla and impede 
percutaneous biliary stent placement, as well as being more likely to migrate. Consequently 
uncovered gastroduodenal stents are most frequently used in gastric outlet obstruction due 
to pancreatic head cancers.  
Simultaneous biliary and gastroduodenal metal stenting can be done in patients with 
inoperable pancreatic cancers causing obstructive jaundice and gastric outlet obstructive 
symptoms (Kaw et al., 2003; Mutignani et al., 2007). Whenever a gastroduodenal stent is to 
be inserted in a pancreatic cancer patient, consideration should be given to initially stenting 
the bile duct. A pre-existing plastic biliary stent can be changed for a wider biliary SEMS 
before the gastroduodenal stent is placed. If the duodenal obstruction does not allow 
passage of the duodenoscope to reach the ampullary region, then transhepatic insertion of a 
biliary SEMS should be considered prior to placing the gastroduodenal stent. 
5. Biliary stents  
5.1 Biliary strictures 
Biliary stents are inserted at Endoscopic Retrograde Cholangio-Pancreatography (ERCP) 
in the setting of malignant bile duct strictures (pancreatic head cancers and 
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cholangiocarcinomas). At ERCP, biliary stents are positioned through a side-viewing 
duodenoscope under direct endoscopic vision, and with fluoroscopic guidance. Despite 
advances in healthcare, most patients with malignant biliary strictures are not surgically 
curable. The obstructive jaundice and pruritus arising from blockage to the flow of bile 
into the duodenum can be very distressing. Endoscopic biliary stenting at ERCP provides 
relief from obstructive jaundice and pruritus, with associated improvement in quality of 
life (Ballinger et al., 1994). Stents used can be plastic or SEMS. Prior to the development of 
endoscopic stenting, relief of obstructive jaundice in unresectable malignant disease 
required a surgical biliary bypass operation. The first endoscopic transpapillary biliary 
stent insertion was performed in 1979 (Soehendra et al., 1980). 
 
  
Fig. 6. Diagram of a SEMS deployed in distal bile duct at ERCP (left panel), and endoscopic 
view of a plastic biliary stent protruding from the duodenal ampulla in a patient with 
pancreatic cancer (right panel) 
5.1.1 Role of stenting in obstructive jaundice due to operable pancreatic head 
carcinoma 
Approximately 20% of patients with pancreatic cancer have localised disease making a 
surgical resection technically possible. Surgical candidates for the required 
pancreaticoduodenectomy (Whipple’s procedure) may require preoperative biliary stenting 
to improve symptoms of obstructive jaundice while awaiting surgery. Furthermore, 
traditional surgical teaching has stated that operating in the presence of obstructive jaundice 
is linked to increased postoperative complications, and that the biochemical correction of 
jaundice preoperatively is linked to fewer surgical complications. However there are now 
increasing data indicating that preoperative biliary drainage using plastic stents may not 
actually be beneficial but may even be associated with more complications, particularly 
from cholangitis (van der Gaag et al., 2010). Therefore, if there is no time delay to surgical 
resection, preoperative biliary drainage using endoscopic stenting is best avoided.  
5.1.2 Biliary stenting v. surgery for jaundice in unresectable pancreatic head carcinoma 
Most (80%) patients with pancreatic head cancers and consequent biliary tract obstruction 
are not candidates for surgical resection. This is because of locally advanced disease 
(particularly infiltration of the major mesenteric vessels) or distant metastases, or patient 
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frailty/comorbidities. Until the advent of biliary stenting, obstructive jaundice and 
pruritus could only be relieved by a palliative surgical biliary bypass procedure 
(cholecystojejunostomy or choledochojejunostomy). The introduction of plastic biliary 
stent placement at ERCP has allowed a non-invasive means of palliating jaundice and 
pruritus. Comparative trials of plastic stent placement with biliary bypass operations have 
shown similar survival outcomes, but stenting is associated with fewer complications, less 
use of resources and a shorter period of hospitalisation (Shepherd et al., 1988; Andersen et 
al., 1989; Smith et al., 1994; Moss et al., 2007). However plastic biliary stenting is 
associated with a higher risk of recurrent biliary obstruction than surgery. There have 
been no direct prospective trials comparing SEMS with biliary bypass surgery.  
5.1.3 Plastic stents v. SEMS in unresectable pancreatic head carcinoma 
Plastic stents tend to become blocked with biliary sludge and bacterial biofilm formation. A 
standard plastic 10 Fr stent may only last 3-5 months. A blocked stent will lead to a 
recurrence of jaundice and frequently cholangitis too. In the setting of inoperable pancreatic 
head cancer, the short life-span of the plastic stent is often greater than the life expectancy of 
the patient. Therefore although there is no doubt that modern biliary SEMS are less likely to 
become blocked (Davids et al., 1992; Moss et al., 2007; Weber et al., 2009), their superior 
patency over plastic stents will not become manifest in pancreatic head cancer patients with 
short life expectancy (Moss et al., 2006; Gronroos et al., 2010). 
 
  
Fig. 7. ERCP images in a patient with carcinoma of head of pancreas. A wire has been placed 
across a stricture of the distal common bile duct into the dilated obstructed biliary system 
above (left hand image). Following insertion of a plastic stent (right hand image).  
Wider plastic stents will remain patent for longer, but 12 Fr currently represents the maximum 
diameter of a plastic biliary stent since it is limited by the diameter of the duodenoscope’s 
operating channel. Biliary stents, whether plastic or metal, traverse the Sphincter of Oddi 
which is the physiological barrier preventing bacteria from the duodenum refluxing into the 
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biliary system. Since occlusion of biliary stents is in part due to bacterial biofilm formation, 
consideration has been given to prolonging stent patency by impregnating stents with 
antimicrobial agents or coating them with silver or hydrophilic polymer which reduce 
bacterial adhesion. However these approaches are based on in vitro observations and have not 
been translated into clinical advantage (Schilling et al., 2003; Donelli et al., 2007). Similarly 
administering oral antibiotics or using the choleretic agent ursodeoxycholic acid does not 
reliably lead to prolongation of plastic stent patency (Galandi et al., 2002). 
For patients with inoperable pancreatic head cancer whose survival is predicted to be 
several months or longer, and for patients who cannot undergo resective surgery for distal 
common bile duct cholangiocarcinomas or ampullary tumours (both slower growing than 
pancreatic cancers), SEMS placement is superior to plastic stent placement. Biliary SEMS 
remain patent for longer periods than plastic stents (Moss et al., 2006). At least in part this is 
due to the fact that the diameter of a biliary SEMS is three times that of plastic stent. Biliary 
SEMS are far more costly than plastic stents, but their use is justified in patients whose 
survival is predicted to be more than 6 months since a repeat endoscopic procedure to 
replace an occluded plastic stent is likely to be needed by then. Although SEMS 
undoubtedly have greater patency, tumour tissue may grow through the gaps in the metal 
mesh leading to subsequent occlusion. The stent can be unblocked by trawling a balloon 
through its lumen, by using diathermy devices or by placing another (metal or plastic) stent 
within it. Tumour ingrowth can be offset by using silicone-covered biliary stents, but as with 
all covered stents these are more likely to migrate, compared to uncovered bare metal stents. 
In the constant quest to improve stent design, a biliary SEMS incorporating a novel 
antireflux device has been developed with the hope that preventing reflux of duodenal 
contents into the biliary tract will aid stent patency (Hu et al., 2011). 
 
 
Fig. 8. SEMS being deployed across a malignant stricture of the common bile duct at 
transhepatic cholangiography 
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5.1.4 Biliary stenting in obstructive jaundice due to unresectable hilar malignancies 
Malignant biliary obstruction at the liver hilum is usually due to cholangiocarcinoma, a 
primary cancer originating from the biliary ductal system (Aljiffry et al., 2009). Metastatic 
cancer infiltrating lymph nodes at the liver hilum can also cause stricturing at this site. 
While the most proximal cholangiocarcinomas originate from either the right or the left 
intrahepatic ductal system, cholangiocarcinomas more commonly involve the confluence of 
the two ductal systems where they join to form the common hepatic duct and are then 
known as hilar tumours. These intrahepatic and hilar chlangiocarcinomas often cause 
obstructive jaundice and pruritus. The only chance of a cure is a hepatic resection, but for 
many patients this is not an option due to advanced disease or due to frailty/comorbidities. 
In unresectable disease, palliation of jaundice and pruritus may be achieved by biliary 
stenting.  
Stenting across malignant hilar strictures can be technically challenging at ERCP. Prior 
imaging of the biliary ductal system using Magnetic Resonance Cholangio-Pancreatography 
(MRCP) provides invaluable information before stenting is attempted. Strictures at the liver 
hilum may be complex and it may not be possible to drain obstructed liver segments at 
ERCP. There is a significant risk of causing cholangitis by injecting contrast medium into 
undrained ductal segments, therefore drainage of contrast-filled obstructed biliary branches 
is crucial. There has been much debate about the importance of establishing drainage of 
both liver lobes in malignant hilar obstruction. Although the right hepatic duct drains a 
greater volume of liver than the left hepatic duct, successful stenting of either side achieves a 
similar symptomatic and biochemical improvement (Polydoru et al., 1989). A randomised 
trial comparing the insertion of a single plastic stent to drain one side of the liver with 
placing two plastic stents to drain both sides, found that there was no advantage in placing 
two stents. Attempts to place two stents were associated with more complications, 
particularly cholangitis (de Palma et al., 2001). Extrapolating from this, it would seem that 
that if endoscopic stenting is to be performed for malignant hilar strictures, then a single 
SEMS is the best strategy. As with distal biliary strictures SEMS are less likely than plastic 
stents to occlude (Perdue at al., 2008).  
Satisfactory biliary drainage of hilar strictures may not be possible at ERCP. Percutaneous 
hepatic drainage and stenting can be performed by an interventional radiologist if initial 
ERCP is unsuccessful, or if following endoscopic stenting there are undrained hepatic 
segments requiring treatment. Percutaneous stenting is performed using local anaesthetic 
and with intravenous sedation. Initial percutaneous transhepatic cholangiography will 
delineate the strictured area at the hilum and, usually after a period of external biliary 
drainage, a stent can be positioned at a second percutaneous transhepatic biliary procedure. 
ERCP and percutaneous transhepatic biliary radiology are thus complimentary 
interventions in the approach to proximal obstructive biliary strictures. There are few data 
comparing endoscopic and percutaneous stenting for hilar strictures. One retrospective 
study concluded that biliary decompression using SEMS was more likely to be successful if 
the SEMS was inserted via the percutaneous transhepatic route than if inserted via the 
endoscopic route (Paik et al., 2009).  
5.2 Biliary stenting for common bile duct stones (choledocholithiasis) 
Choledocholithiasis can lead to pain, obstructive jaundice, acute pancreatitis and cholangitis. 
Endoscopic removal of stones at ERCP is safer than open surgical exploration of the common 
bile duct. Common bile duct stone extraction at ERCP is usually successful using balloon 
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catheters, baskets or lithotripsy after performing endoscopic sphincterotomy or 
sphincteroplasty (Williams et al., 2008). However it is not always possible to clear the common 
bile duct of stones, particularly large stones. The insertion of a stent to splint residual stone(s) 
is a reasonable temporary strategy, although it is preferable to clear the duct completely at a 
later procedure. Biliary stents used to splint common bile duct stone(s) are typically of the 
plastic pigtail variety. They are usually of smaller calibre, typically 7 Fr and inserted over a 
guidewire. The pigtail stent splints the stone within the bile duct, allowing bile to drain around 
it, and does not rely solely on the stent remaining patent. Stent placement for 
choledocholithiasis is a good temporising intervention in the setting of common bile duct 
stone(s) causing jaundice and/or cholangitis (Cairns et al., 1989; Maxton et al., 1995). 
Previously nasobiliary drainage was used as an emergency intervention in patients with life-
threatening supporative cholangitis but the placement of a plastic stent provides as effective 
biliary drainage in this acute emergency (Sharma et al., 2005; Park et al., 2008). 
If intervention at the index ERCP does not clear common bile duct stones and a stent is left 
in situ to provide drainage, then a follow up ERCP or surgical exploration of the common 
bile duct will be necessary (Williams et al., 2008). A second therapeutic ERCP after an 
interval is often successful at clearing the common bile duct (Maxton et al., 1995; Horiuchi et 
al., 2010). Clearing the bile duct is the preferred management course since the retention of 
common bile duct stones and ongoing presence of a plastic splinting stent makes a bout of 
future cholangitis more likely (Bergman et al., 1995; Chopra et al., 1996). Only patients who 
have limited life expectancy, or who have significant comorbidity should have plastic biliary 
stents left as sole therapy for their retained common bile duct stones (van Steenbergen et al., 
1992; Williams et al., 2008). 
5.3 Stenting for biliary leaks following cholecystectomy  
Biliary leaks are not uncommon after cholecystectomy (Lau et al., 2010), and the advent of the 
laparoscopic approach to cholecystectomy has, if anything, made this surgical complication 
more common. Biliary leaks usually become evident in the early post-operative period, and 
may arise from an inadvertent intraoperative bile duct injury, or from the clips on the 
transected cystic duct becoming displaced. Once it is evident that a biliary leak with 
consequent biliary peritonitis is occurring, endoscopic treatment at ERCP is the preferred 
intervention (Tzovaras et al., 2001; Sandha et al., 2004; Agarwal et al., 2006). Endoscopic 
sphincterotomy alone will reduce pressure in the biliary system by equating it with 
intraduodenal pressure. The elimination or reduction in pressure gradient promotes 
preferential flow of bile from the common bile duct into the duodenum instead of 
extravasation via the leak. This allows a more proximal bile duct leak or cystic duct stump leak 
to heal spontaneously. However many endoscopists prefer to insert a temporary plastic stent. 
This can be a short stent across the Sphincter of Oddi, again effectively reducing pressure in 
the biliary system, so that the defect can heal spontaneously (Bjorkman et al., 1995). 
Alternatively a longer stent can be placed to cover the leak. For example in the case of a 
leaking cystic duct stump, a long straight plastic stent might be positioned with the proximal 
end above the junction of the cystic duct and bile duct. Endoscopically-placed plastic stents 
can be removed after approximately 6 weeks, by which time the biliary leak will have healed. 
5.4 Stenting of biliary strictures caused by cholecystectomy or liver transplant 
Bile duct stricturing may complicate bile duct injury at cholecystectomy. Traditionally a 
hepaticojejunostomy has been the definitive treatment for such stricturing after 
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cholecystectomy. However endoscopic access to the common bile duct at ERCP allows 
balloon dilatation and the insertion of a plastic biliary stent across the stricture. If plastic 
stents are routinely changed (to avoid clogging) every 3 months, then after approximately 
one year, stents can then be removed and in most cases the stricturing will not recur (de 
Palma et al., 2003; Vitale et al., 2008). 
Biliary stricturing remains a common problem after orthotopic liver transplantation (Ayoub 
et al., 2010). The two usual types of bile duct reconstruction performed at the time of 
transplantation are duct-to-duct (choledocho-choledochostomy) and hepatico-jejunostomy. 
Duct-to-duct biliary reconstructions allow endoscopic access to the reconstructed bile duct. 
Strictures of the biliary anastomosis are characteristically localised and short. They respond 
well to endoscopic treatment with balloon dilatation and plastic biliary stenting (Seo et al., 
2009). However transplant recipients may also experience non-anastomotic strictures which 
are a consequence of ischaemia or immunological reaction. These non-anastomotic strictures 
may be more diffuse and longer. They respond less well to endoscopic therapy with 
repeated dilatations and stenting (Williams & Draganov, 2009). 
6. Pancreatic stents 
Stenting of the pancreatic duct at ERCP is used in chronic pancreatitis, pancreatic duct leaks 
and the prevention of ERCP-induced pancreatitis. Invariably plastic stents are used in these 
settings. The pancreatic duct is much narrower than the biliary ductal system, and stents in 
the pancreatic duct can induce fibrosis and stricturing.  
6.1 Chronic pancreatitis  
Refractory pain in chronic pancreatitis may be associated with an obstructed pancreatic 
duct. In patients suffering ongoing pain due to chronic pancreatitis, pancreatic stenting 
helps relieve pressure in a pancreatic duct obstructed by an inflammatory stricture or stone, 
often with subsequent pain relief (Wilcox & Varadarajulu, 2006, Weber et al., 2007, Nguyen-
Tang & Dumonceau, 2010). Patients with a dominant pancreatic duct stricture in the 
pancreatic head seem to derive most benefit from such transpapillary stent placement. 
However well-performed prospective controlled studies of pancreatic endoscopic therapy 
for chronic pancreatitis are lacking. Furthermore, pancreatic duct stenting is inferior to 
surgical drainage in relieving pain associated with an obstructed pancreatic duct (Cahen et 
al,, 2007). When pancreatic stents are used in chronic pancreatitis, endoscopists typically use 
stent calibres ranging from 7 Fr to 11.5 Fr, and elective stent changes are needed every 2-3 
months. Smaller calibre stents will occlude more easily and need more frequent changing.  
6.2 Pancreatic duct fistulae  
The pancreatic duct can be disrupted by an attack of acute pancreatitis or following surgery. 
Subsequent pancreatic duct leaks with/without pseudocyst formation can be treated by the 
insertion of a transpapillary pancreatic duct stent (Cicek et al,, 2006). Any discrete 
connection between the pancreatic duct and a pancreatic pseudocyst can be sealed off by the 
insertion of a pancreatic stent.  
6.3 Preventing ERCP-induced pancreatitis  
Acute pancreatitis is a recognised complication of ERCP, occurring in up to approximately 
5% of therapeutic ERCPs (Freeman et al., 1996; Arata et al., 2010). The risk of pancreatitis is 
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greater in some patient categories (Cheng et al., 2006), and may be as great as 20-30% in 
women with Sphincter of Oddi dysfunction. Pancreatic stent placement decreases the risk of 
post-ERCP pancreatitis in high-risk patients (Arata et al., 2010; Choudhary et al., 2011). 
Typically 5 Fr or 3 Fr gauge straight stents are used. Unflanged stents are advantageous in 
this setting since they are more likely to spontaneously dislodge, and a second endoscopic 
procedure to remove the stent is avoided. 
7. Colorectal stents 
Colorectal cancer is usually treated by planned surgery, but many patients present as an 
emergency with acute colonic obstruction. Colorectal SEMS can be used in the treatment of 
acute malignant colonic obstruction as a bridge to definitive surgery. Secondly, some 
patients with colonic cancers which are starting to produce obstructive symptoms may not 
be surgical candidates due to metastatic disease or frailty/comorbidities. These patients can 
be electively palliated using SEMS. 
Colonic SEMSs are usually uncovered and can be inserted with a combination of endoscopy 
and fluoroscopic guidance. Typically an endoscope is used to identify the obstructing cancer, 
and a wire is passed through the stricture and into the proximal bowel. The endoscope is then 
withdrawn and the stent delivery mechanism is fed over the wire. The endoscope can be 
reinserted alongside the stent delivery mechanism and together with fluoroscopy can be used 
to guide the deployment of the stent across the obstructing lesion. For obstructing cancers in 
the proximal colon, stent placement is best achieved using a “through the scope” delivery 
mechanism. The stent delivery mechanism is delivered over a guidewire through the working 
channel of a colonoscope and deployed without removing the colonoscope. 
7.1 Colorectal SEMS for acute colonic obstruction 
Up to 20% of patients with colon cancer initially present with symptoms of acute colonic 
obstruction. Obstruction is more common in the distal colon, which has a smaller calibre 
than the proximal colon. Emergency surgery plays a major role in the management of these 
patients. However, emergency decompressive surgery on the unprepared and obstructed 
bowel, in patients who are often very sick, carries a significant risk of morbidity (32%-64%) 
and mortality (15%-34%) (McLoughlin & Byrne, 2008).  
Emergency surgical decompression invariably involves colostomy formation, since primary 
anastomosis in the setting of an unprepared and obstructed bowel is likely to break down. 
Operations range from a loop colostomy, a Hartmann's procedure or sometimes a subtotal 
colectomy. Following such emergency surgery, a patient with a potentially resectable cancer 
will then require a planned second operation at a later stage. However, in up to 40% patients 
the colostomy becomes permanent and will not be closed because of metastatic disease or 
frailty. 
Placement of a colonic SEMS to relieve the malignant obstruction in the emergency setting 
will spare the patient emergency surgery and colostomy formation. Stenting allows time for 
the patient to recover from acute symptoms, and undergo appropriate cancer staging 
investigations. In patients whose staging investigations confirm operable cancer, stenting as 
a bridge to a definitive resection allows better preparation for the surgery which is less 
likely to then involve stoma formation. In these situations the stent is removed together with 
the resected tumour. In patients whose staging investigations reveal inoperable cancer, the 
stent provides palliation. 
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Early studies showed that colorectal stents inserted under a combination of endoscopic and 
fluoroscopic (Baron et al., 1998) or fluoroscopic guidance alone (Mainar et al., 1996) are safe 
and effective in the treatment of acute malignant colonic obstruction. A randomised study of 
48 patients with obstructing left distal colonic cancers compared SEMS placement followed 
by definitive laparoscopic-assisted colonic resection and conventional emergency open 
surgery. Patients in the SEMS / laparoscopic surgery group were more likely to have a 
successful single stage operation (67% vs 38%), less likely to have a permanent stoma (0% vs 
25%), and less likely to have complications than the emergency surgery group (Cheung et 
al., 2009). In another prospective randomised study, obstructed patients who were stented 
prior to surgery were also more likely to have a primary anastomosis compared to those 
who had emergency surgery (85% vs 41%). They also had fewer complications, re-
interventions and a reduced total hospital and ITU stay (Martinez-Santos et al., 2002). In a 
meta-analysis that included non randomised and somewhat heterogeneous studies 
comparing SEMS and open surgery for malignant large bowel obstruction, mortality was 
5.7% in those undergoing SEMS compared to 12.1% in those having emergency surgery 
(Tilney et al., 2007). 
7.2 Colorectal SEMS for palliation of incurable colonic cancer 
SEMS are also used electively for palliation of symptoms in patients who are frail and not fit 
for surgery, or in cases of advanced cancer. Two small randomised controlled trials have 
compared SEMS to colostomy for the palliation of malignant obstruction (Fiori et al., 2004; 
Xinopoulos et al., 2004). They found that patients who were treated with SEMS spent less 
time in hospital and had a shorter time to oral intake and restoration of bowel function. A 
recent retrospective study from a single centre also showed a high technical and clinical 
success rate for SEMS insertion, with few complications up to 30 days after stent insertion. 
However complications (mainly stent re-obstruction and stent migration necessitating the 
placement of a second stent) after 30 days were higher in patients treated with SEMS than in 
those treated with surgery (Lee et al., 2011).  
7.3 Technical success and complications associated with colorectal SEMS 
Colonic stents have now been used in malignant colorectal obstruction for two decades. 
Two systematic reviews of non randomised studies (Khot et al., 2002; Sebastian et al., 2004) 
conclude that colonic stents can be successfully placed in the majority of cases (92% and 
94%) with a good clinical result (88% and 91%). Complications in these reviews included 
perforation in about 4%, stent migration in 10% and re-obstruction in 10% of patients. Stent 
related mortality is approximately 1%. Based on the available data, the World Society of 
Emergency Surgery and the Peritoneum and Surgery Society advocate the use of colorectal 
stents in preference to colostomy in cases where palliation is needed, and endorse their use 
as a bridge to surgery in cases of acute malignant colonic obstruction (Ansaloni et al., 2010)  
SEMS insertion for benign diseases of the colon is somewhat controversial. The role for 
SEMS in treating benign colonic strictures has yet to be established. 
8. Summary 
Advances in endoscopy and in stent technology in the past 20 years have allowed non-
invasive palliation of obstructive symptoms within the gastrointestinal tract using stents. In 
many clinical scenarios, stent placement has proved advantageous over surgery. 
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Figures of in vitro stents are reproduced with permission from Cook Medical and Olympus. 
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